Lipid Accumulation Product, Visceral Adiposity Index, and Chinese Visceral Adiposity Index As Markers of Cardiometabolic Risk in Adult Growth Hormone Deficiency Patients: A Cross-Sectional Study

Xin Xie, Qing Li, Lingmin Zhang and Wei Ren

Endocrine Practice - Jan 2018, Vol. 24, No. 1 (January 2018) pp. 33-39

Growth hormone (GH) has an irreplaceable metabolic role in the body, especially in adipose tissue, bone and muscle, which are major targets of GH action (1,2). GH deficiency (GHD) in adults is a well-defined clinical condition characterized by abnormal body composition, impaired physical activities, depressed mood, and decreased quality of life (3). Indeed, untreated adult GHD (AGHD) is associated with cardiometabolic risk factors such as glucose intolerance, insulin resistance (IR), dyslipidemia, and altered cardiac structure and function, but GH replacement therapy (GHRT) can combat these outcomes (4–7).